Carfilzomib for relapsed or refractory multiple myeloma - Authors' reply

Lancet Oncol. 2018 Jan;19(1):e2. doi: 10.1016/S1470-2045(17)30920-8.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Humans
  • Multiple Myeloma*
  • Neoplasm Recurrence, Local*
  • Oligopeptides
  • Proteasome Inhibitors
  • Recurrence

Substances

  • Oligopeptides
  • Proteasome Inhibitors
  • carfilzomib